Kornimate/medical-research-clean huggingface dataset:
the clinical trial of cefuroxime axetil dispersible tablets

Conditions: Infectious Disease

Summary: 1. national, large-scale, standardized, standardized, real-world research; 2. prospective, single - arm open, non - interventional, registration, multi - center clinical study; 3. in the use of cefuroxime axetil dispersible tablets in the hospital, according to the principle of voluntary selection of 200; 4. registration of the use of cefuroxime axetil dispersion tablets patients; 5. target sample size of 100,000 cases; 6. exemption from informed consent for ethical review applications; 7. antibiotic drug safety re-evaluation of large data.

research purposes 1. to evaluate the safety of cefuroxime axetil dispersible tablets in the real world of the widely used population, rare or even very rare, new, unanticipated adverse reactions, while revealing adverse reactions should be susceptible to risk factors and susceptible populations. 2. to evaluate the efficacy of cefuroxime axetil dispersible tablets in the treatment of the relevant site of infection, including including empirical therapy and targeted therapy, to further evaluate the widespread use of cefuroxime dispersible tablets the validity of the crowd in the real world. 3. to investigate the clinical application of cefuroxime axetil dispersible tablets for the safety management of drug use. clinical management should provide more clinical clues and basis. 4. for the relevant treatment areas of guidance and consensus revision, clinical pathway design provides a reference. 5. to further improve the safety of cefuroxime axetil dispersion tablets level, the basic medical security capabilities and market vitality. study end point 1. the main study endpoint: * security; * effectiveness. 2. secondary study endpoint: * extensive use of population characteristics; * clinical drug characteristics; * appropriate characteristics of the crowd; * adverse reactions susceptible population characteristics.

Eligibility criteria:
inclusion criteria: * prescription of cefuroxime axetil dispersible tablets in patients exclusion criteria: * no
bacteriostatic saline as a local anesthetic in minor eyelid procedures

Conditions: Eyelid Tumor; Eyelid Bump; Eyelid Deformity; Eyelid Abscess; Eyelid Boil; Eyelid Papilloma; Anesthesia, Local; Ophthalmology

Summary: the investigators aim to assess whether bacteriostatic saline provides the same level of anesthesia as traditional local anesthesia while reducing pain associated with medication infusion in minor eyelid procedures

benzoyl alcohol is an aromatic alcohol that has been used in healthcare primarily as an antibacterial preservative agent in bacteriostatic saline. it has also been shown to have anesthetic properties, and has been demonstrated to cause less pain with infusion compared to lidocaine, while maintaining adequate pain relief. the use of bacteriostatic saline alone as an anesthetic for incisional procedures in the periocular area has not yet been studied. the purpose of this study was to determine whether bacteriostatic saline provides an adequate level of anesthesia for minor in-office eyelid procedures while allowing for reducing pain associated with medication infusion compared with traditional local anesthetic agents. to assess this, the investigators will recruit 150 patients aged 18 or older undergoing minor eyelid procedures including eyelid biopsies, chalazion removal from outpatient oculoplastics clinics at ucsf. patients will be randomized in a 1:1 fashion to undergo local anesthetic with either 1% lidocaine with 1:100,000 epinephrine or 0.9% bacteriostatic saline. primary outcome measure will be pain level on a scale of 1-10 with regards to injection and procedure itself. these will be compared between the two groups. the investigators hypothesize that bacteriostatic saline is superior to lidocaine with epinephrine in terms of pain with injection, but will result in a similar pain level during the procedure.

Eligibility criteria:
inclusion criteria: 1. age \>=18 years old 2. undergoing clinic-based periocular procedure exclusion criteria: 1. any other topical, oral or intravenous sedating medications given alongside procedure 2. allergy to saline, lidocaine or epinephrine 3. unable to provide consent due to cognitive impairment

Keywords: oculoplastics local anesthesia eyelid anesthesia periocular anesthesia
halliwick hydrotherapy and snoezelen

Conditions: Autism Spectrum Disorder; Autism; Sensory Disorder

Summary: the aim of this study was to evaluate the effectiveness of the halliwick concept in the adapted snoezelen multi-sensory environment, in the gross mobility of children belonging to the autism spectrum.

the study involved 54 children, aged 4 to 8, all of whom belonged to the autism spectrum (asd) and all had cognitive limitations. the duration of the intervention was 3 months by specialized pediatric physiotherapists and hydrotherapists certified by the program "pediatric specialization" and ndt- bobath. all children were assessed through the wota 1 and pedi assessment tests.

Eligibility criteria:
inclusion criteria: * children aged 4-8 years with autism * all participants had the criterion of participation in the monitoring treatment program by the same therapist either in water or on land. exclusion criteria: * children with other neurological diseases were excluded. * children who had some scheduled surgery were also excluded intervention or injection of sausage toxin. * children who were absent from the treatment program were excluded either in water or on land for more than a week.
dual mobility total joint prosthesis (touch) for thumb carpometacarpal joint osteoarthritis

Conditions: Rhizarthrosis

Summary: the dual mobility concept currently represents the newest generation of thumb carpometacarpal prostheses. the aim of this study was to evaluate the outcomes of touch® prosthesis. from september 2019 to december 2023,a minimum of 100 prosthesis shall be implanted in patients suffering from symptomatic stage iii osteoarthritis. all included patients will follow a systematic follow-up regimen (4, 8, 16 weeks, 6, and 12 months as well as 24 months postoperatively). radiographics, rom, vas, dash and pinch grip are measured. aim of the study is to compare clinical outcome of dual mobility prosthesis with common results of cmc i prosthesis in literature.

the dual mobility concept currently represents the newest generation of thumb carpometacarpal prostheses. the aim of this study was to evaluate the outcomes of touch® prosthesis. from september 2019 to december 2023,a minimum of 100 prosthesis shall be implanted in patients suffering from symptomatic stage iii osteoarthritis. all included patients will follow a systematic follow-up regimen (4, 8, 16 weeks, 6, and 12 months as well as 24 months postoperatively). radiographics, rom, vas, dash and pinch grip are measured. aim of the study is to compare clinical outcome of dual mobility prosthesis with common results of cmc i prosthesis in literature. the study is designed to give clinical results after one year, 2 years and also long time results in the future.

Eligibility criteria:
inclusion criteria: * cmc i osteoarthritis /stage iii) exclusion criteria: * cmc i (osteoarthritis / other stage than iii) * anticoagulation

Keywords: cmc i osteoarthritis, total joint replacement, hand surgery
vertos mild - post market patient outcomes

Conditions: Lumbar Spinal Stenosis

Summary: this is a single-center study evaluating the outcomes of patients with painful lumbar spinal stenosis who were treated with the mild procedure (minimally invasive lumbar decompression. the patients will be followed for 6 months after the procedure.

approximately 50 patients at a single center will be enrolled and followed for a period of up to 26 weeks. adult patients with symptomatic lumbar spinal stenosis who meet the enrollment criteria will be offered the mild procedure as an alternative to surgery or continued standard non-surgical medical management.

Eligibility criteria:
inclusion criteria: * symptomatic and lumbar spinal stenosis caused by dorsal element hypertrophy * prior failure of conservative therapy and oswestry disability index (odi) \>20% * radiologic evidence of lumbar spinal stenosis, ligamentum flavum hypertrophy (typically \>2.5mm),confirmed by pre-op mri/ct report * central canal cross sectional area clearly reduced per mri/ct report * if present, anterior listhesis \< or = to 5.0mm (preferred) and deemed stable by the investigator * able to walk at least 10 feet unaided before being limited by pain * available to complete 26 weeks of follow up * a signed consent form is obtained from the patient * adults 18 years of age or older exclusion criteria: * prior surgery at the intended treatment level * compound fracture with intraspinal retropulsion contributing to spinal stenosis * disabling back or leg pain from causes other than lumbar spinal stenosis * disc protrusion or osteophyte formation severe enough to confound study outcome * facet hypertrophy severe enough to confound study outcome * bleeding disorders and/or current use of anti-coagulants * use of acetylsalicylic acid (asa) and/or non-steroidal anti-inflammatory drug (nsaid) within 5 days of treatment * epidural steroids with 3 weeks prior to procedure * inability of patient to lie prone for any reason with anesthesia support * metabolic wound healing pathologies that may be deemed by the investigator to compromise the study outcomes * dementia and/or inability to give informed consent * pregnant and/or breastfeeding * on workman's compensation or considering litigation associated with back pain
improving prognostic confidence in neurodegenerative diseases causing dementia using peripheral biomarkers and integrative modeling

Conditions: Dementia; Alzheimer Disease; Dementia with Lewy Bodies; Vascular Dementia; Frontotemporal Dementia; Mild Cognitive Impairment; Corticobasal Syndrome; Progressive Supranuclear Palsy; Parkinson Disease; Primary Progressive Aphasia

Summary: to develop a model to predict disease progression in a large cohort of patients across a variety of neurodegenerative diseases, including mild cognitive impairment (mci) and dementia due to any neurodegenerative disease, including alzheimer's disease (ad), lewy body disease (lbd), vascular disease (vad) and frontotemporal lobar degeneration (ftld).

the goal of this study is to create a model to predict disease progression in patients with mild cognitive impairments and forms of dementia. to accomplish this, the current study will evaluate different tests including: brain imaging (mri), body fluid samples (blood and cerebrospinal fluid), skin biopsy, cognitive ability, and behavioural questionnaires. the study team hopes that this information can be used to guide diagnosis and better predict disease progression in patients with mild cognitive impairment and and early dementia.

Eligibility criteria:
inclusion criteria: * referring diagnosis of mci or early dementia * age 40-95 * study partner who has some weekly contact with patient. some of the neuropsychological assessment require collateral from close contacts to assess cognition and functioning. since neurodegenerative diseases can be associated with reduced cognition, including reduced awareness of one's own impairments, participants will be assessed for their capacity to consent at all study visits. * must, in the opinion of the site investigator, be able to complete most study procedures. exclusion criteria: * participants who are not able to complete the majority of assessments in the opinion of the pi are excluded from the study. exclusion criteria are evaluated at the site investigator's discretion; if the site investigator believes that the participant's symptoms are due to causes other than neurodegeneration, despite the presence of an exclusionary condition, the investigator may overrule the exclusion.
effectiveness of eplerenone to improve target organ damage in patients with resistant arterial hypertension

Conditions: Essential Hypertension

Summary: resistant hypertension is defined as hypertension not controlled (i.e. blood pressure not below 140/90 mmhg) with the use of adequate doses of at least three different anti-hypertensives including a diuretic. resistant hypertension is abundant. in the allhat trial 34% of patients did not reach the blood pressure goal of 140/90 mmhg. one possible mechanism of resistance is the aldosterone-escape phenomenon. during aldosterone escape, aldosterone plasma levels are normal or even elevated despite therapy with aceis or arbs. the prevalence is about 30-50%. possible reasons for aldosterone escape are alternative ways of aldosterone stimulation (hyperkalemia, adrenomedullin, acth), local aldosterone production or primary aldosteronism. aldosterone has deleterious blood pressure independent effects on cardiac, vascular and renal damage. hypothesis: eplerenone is effective to improve hypertensive target organ damage in patients with resistant hypertension.

see above

Eligibility criteria:
inclusion criteria: * casual blood pressure \>=140/90 despite effective triple therapy including an acei/arb and a diuretic exclusion criteria: * contraindication for eplerenone * creatinine-clearance \< 60 ml/min * diabetes mellitus

Keywords: essential hypertension
investigating the effects of krill oil and krill protein on post-exercise muscle protein metabolism

Conditions: Hypertrophy

Summary: the aim of the current study is to find out if krill oil can increase muscle building processes in response to resistance (weightlifting) type exercise. others aim are to determine the effects of krill protein, and the interaction of krill oil and protein, on muscle building processes in response to resistance (weightlifting) type exercise.


Eligibility criteria:
inclusion criteria: * be 60 years old or older * have a bmi of less than 35kg/m2 * be participating in structured exercise for less than 2h per week exclusion criteria: * diabetes * severe cardiovascular disease * seizure disorders, * uncontrolled hypertension (\>150/90mmhg at baseline measurement) * cancer or cancer that has been in remission \<5 years * ambulatory impairments which would limit ability to perform assessments of muscle function * dementia * taking medication known to affect muscle (e.g., steroids) * have an implanted electronic device (e.g., pacemaker/defibrillator/insulin pump), * anticoagulant therapy * allergies to seafood * regular consumption of more than 1 portion of oily fish per week.

Keywords: omega-3 krill oil protein exercise
efficacy, safety and pharmacokinetics of different regimens of indacaterol

Conditions: Persistent Asthma

Summary: this study assessed the bronchodilator efficacy of three different regimens of indacaterol in patients with asthma


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of asthma and: * receiving daily treatment with inhaled corticosteroid in a regimen that has been stable for at least a month prior to screening * fev1 ≥50% and ≤90% of predicted normal at screening * an increase of ≥12% and ≥200 ml in fev1 over prebronchodilator value within 30 minutes after inhaling a total dose of albuterol/salbutamol of 360/400 mdi exclusion criteria: * smoking history of ≥ 10 years * patients with a diagnosis of copd * patients who have been previously intubated for a severe asthma exacerbation/ attack * patients who have experienced a severe asthma attack/exacerbation requiring hospitalization in the 6 months prior to screening * patients who have had an emergency room visit for an asthma attack/exacerbation within 6 weeks prior to screening * patients who have had a respiratory tract infection within 6 weeks prior to screening * patients with seasonal allergy whose asthma is likely to deteriorate during the study period * patients with type i or uncontrolled type ii diabetes mellitus other protocol-defined inclusion/exclusion criteria may apply

Keywords: indacaterol asthma bronchodilation beta-agonist
us clinical study of the apnex medical hypoglossal nerve stimulation (hgns) system to treat obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: the overall goal of the study is to evaluate the safety, efficacy and therapy settings of the hypoglossal nerve stimulation (hgns) system for stimulating the hypoglossal nerve to help maintain airway opening in subjects with obstructive sleep apnea (osa).


Eligibility criteria:
eligibility criteria 1. previously diagnosed with moderate-to-severe obstructive sleep apnea. 2. subject has failed or does not tolerate cpap treatment. 3. age between 21 and 70 years. 4. body mass index (bmi) less than or equal to 37.

Keywords: obstructive sleep apnea osa hypoglossal nerve stimulation sleep apnea
phase ii study of revlimid®, oral cyclophosphamide and prednisone for patients with newly diagnosed multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this study to explore the combination of revlimid®, oral cyclophosphamide and prednisone (rcp) in patients with newly diagnosed multiple myeloma.

this is a phase ii single institution trial in patients with newly diagnosed multiple myeloma. revlimid® 25 mg p.o. daily on days 1-21 of each 28-day cycle. cyclophosphamide 50 mg p.o. bid daily on days 1-21 of each 28-day cycle. prednisone 50 mg p.o. q.o.d..

Eligibility criteria:
inclusion criteria: patients with newly diagnosed, symptomatic multiple myeloma based on the following criteria: * presence of an m-component in serum and/or urine plus clonal plasma cells in the bone marrow and/or a documented clonal plasmacytoma plus one or more of the following: * calcium elevation (11.5 mg/dl) \[42.65 mmol/l\] * renal insufficiency (1.5 x the uln of serum creatinine) * anemia (hemoglobin \<=10 g/dl or 2 g/dl \<= normal) * bone disease (lytic lesions or osteopenia) measurable disease is defined at least one of the following three measurements: * serum m-protein \>=1 g/dl ( or 10 g/l) * urine m-protein \>=200 mg/24 h * serum flc assay: involved flc level \>=10 mg/dl (\>=100 mg/l) provided serum flc ratio is abnormal * measurable plasmacytoma * note: if a patient meets the criteria for symptomatic multiple myeloma but does not meet serum m-protein, urine m-protein or serum flc levels stated above, percent plasma cells in bone marrow will be used to follow response. laboratory test results within these ranges: * absolute neutrophil count \>= 1.0 x 109/l * platelet count \>= 50 x 10(9)/l * hemoglobin \>= 9 gm/dl * serum creatinine \<= 2.5mg/dl. * total bilirubin \<=1.5 x upper limit of normal * ast (sgot) and alt (sgpt) \<= 3 x uln exclusion criteria: * known hypersensitivity to thalidomide * the development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs. * patients with a solitary plasmacytoma * patients with uncontrolled diabetes * patients with ≥ grade 3 sensory neuropathy * history of cardiac disease, with nyha class ii or greater

Keywords: multiple myeloma revlimid
evaluation of effectiveness and safety of xa inhibitor for the prevention of stroke and systemic embolism in a nationwide cohort of japanese patients diagnosed as non-valvular atrial fibrillation

Conditions: Non-valvular Atrial Fibrillation

Summary: the efficacy and safety of a novel oral xa inhibitor for stroke and systemic embolism, namely rivaroxaban, in non-valvular atrial fibrillation patients are evaluated in japanese clinical practice.


Eligibility criteria:
inclusion criteria: patients who meet all the criteria below * patients aged over 20 years * patients diagnosed with non-valvular atrial fibrillation * patients who are treated or will be treated with rivaroxaban * patients from whom written informed consent has been obtained exclusion criteria: patients who meet any of the criteria below * the following patients in whom rivaroxaban is contraindicated for use * patients with a history of allergies to the ingredients contained in this drug * patients having a hemorrhagic event (intracranial hemorrhage, gastrointestinal hemorrhage or other clinically significant hemorrhagic events) * patients having liver disease complicated with coagulation disorder or those having moderate or worse liver disorder (grade b or c in accordance with the child-pugh classification) * patients having renal failure (creatinine clearance: \<15 ml/min) * women who are or are likely to be pregnant * patients who are treated with hiv protease inhibitors (including ritonavir, atazanavir and indinavir) * patients who are treated with oral or injectable formulations of azole antifungal drugs (including itraconazole, voriconazole and ketoconazole (excluding fluconazole))

Keywords: rivaroxaban non-valvular atrial fibrillation noac xa inhibitor
adma and mechanical ventilation in preterm infants

Conditions: Premature Birth

Summary: the purpose of this study is to study the relation between mechanical ventilation and adma concentrations at birth.

nitric oxide (no) plays an important role in the normal development and maturation of the lungs. in addition, no is an important mediator of vascular smooth muscle relaxation, ventilation perfusion matching, neurotransmission and host defence and bacteriostasis. asymmetric dimethylarginine (adma) is an endogenous derivative of arginine that inhibits nos and thereby the bioavailability of no. preterm infants have increased concentrations of adma. therefore, inhibition of no by increased concentrations of adma which could be associated with reduced pulmonary functioning.

Eligibility criteria:
inclusion criteria: * gestational age \< 32 weeks * birth weight \< 1500 gram * written informed consent of parents exclusion criteria: * congenital abnormalities * chromosomal abnormalities

Keywords: adma preterms infants mechanical ventilation preterm infants
the swedish biofinder - preclinical ad study

Conditions: Alzheimer Disease; Mild Cognitive Impairment; Mild Dementia

Summary: this research study aims to examine biomarkers of alzheimer's disease (ad) as early as possible which could potentially be a screening tool for the general population. this observational study will take place at the skåne university hospital in sweden. the study will enroll up to 600 cognitively healthy subjects aged 50 to 80 years with 3/4 having preclinical alzheimer's disease. recruitment and enrollment will be ongoing for 2-3 years, and subject participation will be lasting approximately 4 years. disclosure of ad risk assessments will be an optional procedure.


Eligibility criteria:
inclusion criteria: 1. age 50-80 2. individuals aged 50-60 require at least one of the following risk factors for ad: 1. known apoe-e4 carrier 2. known 1st degree family history of dementia or severe memory loss with onset prior to 75. 3. known amyloid brain pathology by either csf or pet scan. 3. mini-mental state examination (mmse) ≥26 (aged \>65); mmse ≥27 (aged 50-65). 4. score of 12 or above on the montreal cognitive assessment (moca) telephone version. 5. speaks and understands swedish to the extent that an interpreter is not necessary to fully understand the study information and cognitive tests. 6a. preclinical ad subgroup (n=450): amyloid pathology according to csf ad biomarkers and aβ-pet scans. 6b. non-preclinical ad subgroup (n=150): no sign of preclinical ad using csf ad biomarkers or aβ-pet scans. exclusion criteria: 1. fulfils the criteria for minor or major neurocognitive disorder according to the diagnostic and statistical manual of mental disorders, fifth edition (dsm-5). 2. history of significant brain injury or other known neurologic disease or insult, resulting in lasting cognitive sequelae that would confound the assessment and staging of potential neurodegenerative disease. 3. major depression, bipolar disorder, or recurrent psychotic disorders within the past year. 4. history of alcohol and/or substance abuse or dependence within the past year. 5. significant unstable systemic illness or organ failure, such as terminal cancer, that makes it difficult to participate in the study. 6. refusing or unable to complete baseline cognitive and biomarker assessments (i.e., cognitive testing, blood draw, mri and pet).

Keywords: preclinical alzheimer, early diagnosis, biomarkers, plasma, csf, pet